Skip to search formSkip to main contentSkip to account menu

CI 930

Known as: CI-930 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Solid‐phase synthesis and evaluation of libraries of substituted 4,5‐dihydropyridazinones as vasodilator agents
The solid‐phase parallel preparation of a library of 4,5‐dihydropyridazin‐3(2H)‐one derivatives substituted at position 6 with… 
1996
1996
Rapid regulation of a cyclic AMP-specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells.
1992
1992
Differential Hemodynamic Responses to Selective Inhibitors of Cyclic Nucleotide Phosphodiesterases in Conscious Rats
Summary: Selective inhibition of either the low Km cyclic AMP (cAMP) or low Km cyclic GMP (cGMP) phosphodiesterase (PDE) promotes… 
1991
1991
Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta.
1990
1990
Sodium nitroprusside potentiates the depressor response to the phosphodiesterase inhibitor zaprinast in rats.
1990
1990
Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects.
Cyclic nucleotide phosphodiesterase (PDE) isozymes isolated by DEAE-Sephacel or Mono-Q High Performance Liquid Chromatography… 
1990
1990
Effects of CI-930, a novel phosphodiesterase III inhibitor, on platelet aggregation and arachidonic acid metabolism.
In the platelet-rich plasma of rabbits, 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-5-methyl-3(2H)-pyridazinone (CI-930) inhibited… 
Review
1989
Review
1989
Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase.
1987
1987
Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
1987
1987
Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)